Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells.

Link EK, Brandmüller C, Suezer Y, Ameres S, Volz A, Moosmann A, Sutter G, Lehmann MH.

Vaccine. 2017 Sep 12;35(38):5131-5139. doi: 10.1016/j.vaccine.2017.08.019. Epub 2017 Aug 14.

PMID:
28818566
2.

Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox.

Kremer M, Suezer Y, Volz A, Frenz T, Majzoub M, Hanschmann KM, Lehmann MH, Kalinke U, Sutter G.

PLoS Pathog. 2012;8(3):e1002557. doi: 10.1371/journal.ppat.1002557. Epub 2012 Mar 1.

3.

N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection.

Gratz MS, Suezer Y, Kremer M, Volz A, Majzoub M, Hanschmann KM, Kalinke U, Schwantes A, Sutter G.

J Virol. 2011 Apr;85(7):3557-69. doi: 10.1128/JVI.01191-10. Epub 2011 Jan 26.

4.

Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells.

Flechsig C, Suezer Y, Kapp M, Tan SM, Löffler J, Sutter G, Einsele H, Grigoleit GU.

Cytotherapy. 2011 Jul;13(6):739-52. doi: 10.3109/14653249.2010.549123. Epub 2011 Jan 20.

PMID:
21250864
5.

CD40 ligand-triggered human dendritic cells mount interleukin-23 responses that are further enhanced by danger signals.

Sender LY, Gibbert K, Suezer Y, Radeke HH, Kalinke U, Waibler Z.

Mol Immunol. 2010 Mar;47(6):1255-61. doi: 10.1016/j.molimm.2009.12.008. Epub 2010 Jan 13.

PMID:
20071030
6.

Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells.

Halle S, Dujardin HC, Bakocevic N, Fleige H, Danzer H, Willenzon S, Suezer Y, Hämmerling G, Garbi N, Sutter G, Worbs T, Förster R.

J Exp Med. 2009 Nov 23;206(12):2593-601. doi: 10.1084/jem.20091472. Epub 2009 Nov 16.

7.

MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.

Kreijtz JH, Suezer Y, de Mutsert G, van Amerongen G, Schwantes A, van den Brand JM, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.

PLoS One. 2009 Nov 12;4(11):e7790. doi: 10.1371/journal.pone.0007790.

8.

Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.

Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.

Vaccine. 2009 Oct 23;27(45):6296-9. doi: 10.1016/j.vaccine.2009.03.020.

PMID:
19840663
9.

Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression.

Lehmann MH, Kastenmuller W, Kandemir JD, Brandt F, Suezer Y, Sutter G.

J Virol. 2009 Mar;83(6):2540-52. doi: 10.1128/JVI.01884-08. Epub 2009 Jan 7.

10.

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

Kreijtz JH, Suezer Y, de Mutsert G, van den Brand JM, van Amerongen G, Schnierle BS, Kuiken T, Fouchier RA, Löwer J, Osterhaus AD, Sutter G, Rimmelzwaan GF.

J Infect Dis. 2009 Feb 1;199(3):405-13. doi: 10.1086/595984.

PMID:
19061423
11.

Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox.

Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S, Katz L, Preuss T, Hanschmann KM, Kalinke U, Erez N, Levin R, Velan B, Löwer J, Shafferman A, Sutter G.

J Infect Dis. 2009 Jan 1;199(1):39-48. doi: 10.1086/595565.

PMID:
19012492
12.

Vaccination with a Modified Vaccinia Virus Ankara-based vaccine protects mice from allergic sensitization.

Albrecht M, Suezer Y, Staib C, Sutter G, Vieths S, Reese G.

J Gene Med. 2008 Dec;10(12):1324-33. doi: 10.1002/jgm.1256.

PMID:
18816482
13.

Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions.

Veits J, Römer-Oberdörfer A, Helferich D, Durban M, Suezer Y, Sutter G, Mettenleiter TC.

Vaccine. 2008 Mar 20;26(13):1688-96. doi: 10.1016/j.vaccine.2008.01.016. Epub 2008 Feb 4.

PMID:
18291561
14.

Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.

Antonis AF, van der Most RG, Suezer Y, Stockhofe-Zurwieden N, Daus F, Sutter G, Schrijver RS.

Vaccine. 2007 Jun 15;25(25):4818-27. Epub 2007 Apr 20.

PMID:
17499893
15.

Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.

Kreijtz JH, Suezer Y, van Amerongen G, de Mutsert G, Schnierle BS, Wood JM, Kuiken T, Fouchier RA, Lower J, Osterhaus AD, Sutter G, Rimmelzwaan GF.

J Infect Dis. 2007 Jun 1;195(11):1598-606. Epub 2007 Apr 17.

PMID:
17471429
16.

Vaccinia virus replication is not affected by APOBEC3 family members.

Kremer M, Suezer Y, Martinez-Fernandez Y, Münk C, Sutter G, Schnierle BS.

Virol J. 2006 Oct 19;3:86.

17.

Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara.

Staib C, Suezer Y, Kisling S, Kalinke U, Sutter G.

J Gen Virol. 2006 Oct;87(Pt 10):2917-21.

PMID:
16963750
18.
19.

Supplemental Content

Loading ...
Support Center